Screener
Nuvectis Pharma, Inc. NVCT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| (Decrease)/increase in accounts payable | (1,579) | 494 |
| (Decrease)/increase in accrued liabilities | (79) | 25 |
| Decrease in employee compensation and benefits | (460) | (519) |
| Net cash used in operating activities | $(6,511) | $(4,174) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Net cash provided by (used in) investing activities | — | — |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Proceeds from issuance of common shares - At-the market offering | $7 | $1,273 |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s operating cash flow?
- Nuvectis Pharma, Inc. (NVCT) reported operating cash flow of -$6.51M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s operating cash flow changed year-over-year?
- Nuvectis Pharma, Inc.'s operating cash flow decreased by 56.0% year-over-year, from -$4.17M to -$6.51M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s operating cash flow?
- Over 3 years (2022 to 2025), Nuvectis Pharma, Inc.'s operating cash flow has grown at a 5.7% compound annual growth rate (CAGR), from -$13.56M to -$16.01M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Nuvectis Pharma, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude